MSD Animal Health Receives Marketing Approval from European Medicines Agency for BRAVECTO™ (fluralaner) Spot-On Solution for Cats and Dogs
Dateline City:
MADISON, N.J.
Spot-On Treatment for Fleas and Ticks Effective For 12 Weeks
MADISON, N.J.--(BUSINESS WIRE)--MSD Animal Health (known as Merck Animal Health in the United States and
Canada) today announced that, following a positive opinion from the
Committee for Medicinal Products for Veterinary Use (CVMP), the European
Medicine Agency has granted a marketing authorization for the veterinary
medicinal product BRAVECTO™ (fluralaner) Spot-On Solution for both cats
and dogs, a Spot-On treatment for fleas and ticks effective for 12 weeks
following a single dose.
Language:
English
Contact:
MSD Animal HealthMedia:Amy Firsching, +1 973 937 5453amy.firsching@merck.comorPam Eisele, 267-305-3558pamela_eisele@merck.com
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more
Source: Merck - Category: Pharmaceuticals Tags: Animal Health #MSD $MRK Bravecto MSD Animal Health Source Type: news
More News: European Medicines Agency (EMA) | Health | Marketing | Merck | Pharmaceuticals | Veterinary Research